Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Amy S. Clark, MD, MSCE

Amy S. Clark, MD, MSCE Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Clark is employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Internal Medicine, 2009
  • Medical Oncology, 2012

Clinical Expertise:

  • Adjuvant Chemotherapy
  • Aromatase Inhibitor
  • Atypical Ductal Hyperplasia
  • Brca
  • Breast Cancer
  • Breast Cancer Chemotherapy
  • Breast Cancer During Pregnancy
  • Breast Cancer Follow Up
  • Breast Cancer Genetics
  • Breast Cancer High-Risk Counseling
  • Carcinoma In Situ of Breast
  • Cystosarcoma Phylloides
  • ER Negative Breast Cancer
  • ER Positive Breast Cancer
  • Family History of Breast Cancer
  • Herceptin
  • Hereditary Breast and Ovarian Cancer
  • Immunotherapy
  • Inflammatory Breast Cancer (IBC)
  • Invasive Breast Cancer
  • Lobular Neoplasia
  • Male Breast Cancer
  • Neoadjuvant Chemotherapy
  • Sentinel Lymph Node Biopsy
  • Tamoxifen
  • Triple-Negative Breast Cancer
Show All Expertise

Practice Locations and Appointments

  • Rena Rowan Breast Center

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 3rd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-7366 (PENN)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Penn State Milton S. Hershey Medical Center
Residency: Boston Medical Center (Formerly Boston City Hospital)
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Society of Clinical Oncology, National

Hospital Affiliation

Dr. Clark is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

My research focuses on clinical trials and drug development for those with early stage and metastatic breast cancer. I also seek to develop novel predictive biomarkers specifically using molecular imaging as companions to early phase trials.

Selected Publications:

Shah PD, Zarrin H, Wethington S, Latif N, Martin L, Rodriguez D, Elkins K, Giuntoli R, Burger R, Tanyi J, Morgan M, Domchek SM, Gailliard A, Armstrong DK, Simpkins F: Combination ATR and PARP Inhibitor (CAPRI) for Recurrent, Platinum-Resistant Ovarian Cancer AACR Ovarian Cancer Research Meeting : 2019.

Bardia, A., Hurvitz, S., DeMichele, A., Clark, A.S., Zelnak, A., Yardley, D., Karuturi, M., Sanft, T., Blau, S., Hart, L., Mia, C., Caria, N., Purkayastha, D., Mistry, A., Moulder, S.: Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): efficacy, safety, and biomarker results ASCO 2019 – TRINITI-1, Chicago Illinois : 2019.

Dreyfuss AD, Barsky AR, Taunk NK, Clark AS, Freedman GM: The Efficacy and Safety of Hypofractionated Radiotherapy with Concurrent Anti-HER-2 Therapy Following Breast-Conserving Therapy for Breast Cancer The Breast Journal : 2019.

Mankoff DA, Clark AS: PET oestrogen receptor imaging: ready for the clinic? The Lancet Oncology : 2019.

Elmi, A., Makvandi, M., Weng, C.C., Hou, C., Clark, AS., Mach, R.H., Mankoff, D.A.: Cell-proliferation imaging for monitoring response to CDK4/6 inhibition combined with endocrine-therapy in breast cancer: Comparison of [18F]FLT and [18F]ISO-1 PET/CT. Clin Cancer Res : 2019.

Pomponio MK, Keele LJ, Fox KR, Clark AS, Matro JM, Shulman LN, Tchou JC: Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple negative breast cancer? Breast Cancer Research and Treatment : 2019.

Demissei BG, Finkelman B, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, Narayan HK, Narayan V, Waxman AJ, Domchek SM, DeMichele A, Shah P, Clark AS, Bradbury A, Carver JR, Upshaw J, Armenian SH, Liu P, Ky B: Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy Cancer In Press : 2019.

Nanda R, Liu M, Yau C, Shatsky R, Pusztai L, Wallace A, Chien JA, Forero-Torres A, Ellis E, Han H, Clark AS, Albain K, Boughey J, Jaskowiak N, Elias A, Isaacas C, Kemmer K, Helsten T, Maure M, Stinger-Reasor E, Parker C, Lee M, Haddad T, Cohen R, Asare S, Wilson A, Hirst G, Singhrao R, Asare A, Matthews J, Berry S, Schwab R, Symmans W, van't Veer L, Yee D, DeMichele A, Hylton N, Oerlmutter J, Rugo H, Berry D, Esserman L: Pembrolizumab for Early-Stage, High-Risk, HER2-Negative Breast Cancer: Results from the I-SPY2 Trial New England Journal of Medicine : 2019.

McDonald, E.S., Carlin, S., Doot, R.K., Nayak, A., Schubert, E., Pantel, A., Tchou, J., Farwell, M., Pyrma, D., Lee, H., Shah, P., Clark, A.S., Ziober, A., Sheffer, R., Palmer, K., Matro, J., Feldman, M., DeMichele, A., Domchek, S.M., Maxwell, K., Cruz, L., Knollman, H., Anderson, D., Makvandi, M., Schnall, M., Hubbard, R., Mach, R.H., Mankoff, D.A.: PET Imaging of PARP-1 Expression in Breast Cancer San Antonio Texas Breast Cancer Symposium® : 2018.

Venigalla, S., Carmona, R., Guttmann, D.M., Jain, V., Freedman, G.M., Clark, A.S., Shabason, J.E.: Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men. JAMA oncology 4 (10): e181114,2018.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-154
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 662-7096
Patient appointments: 800-789-7366 (PENN)